









Markets
/
Stocks
/
nasdaq-sln
/

Silence Therapeutics PLC

SLN

6.610USD

-0.550-7.68%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

936.65MMarket Cap

LossP/E TTM



Silence Therapeutics PLC

6.610

-0.550-7.68%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Silence Therapeutics PLC

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Silence Therapeutics PLC's Score

Industry at a Glance

Industry Ranking

160 / 407

Overall Ranking

293 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

33.800

Target Price

+372.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Silence Therapeutics PLC Highlights

StrengthsRisks

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 99.76% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 43.26M.

Overvalued

The company’s latest PE is -11.73, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 19.95M shares, decreasing 42.52% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 1.77K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.94, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 224.00K, representing a year-over-year decrease of 70.31%, while its net profit experienced a year-over-year decrease of 39.34%.

Score

Industry at a Glance

Previous score

5.94

Change



Financials

6.22

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.39

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Silence Therapeutics PLC's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 6.24, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -11.73, which is -63.54% below the recent high of -4.28 and -422.06% above the recent low of -61.22.

Score

Industry at a Glance

Previous score

6.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 160/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Silence Therapeutics PLC is 30.00, with a high of 75.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

33.800

Target Price

+372.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Silence Therapeutics PLC

SLN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 6.54, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 7.92 and the support level at 5.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.60

Change

-2.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.046

Neutral

RSI(14)

53.367

Neutral

STOCH(KDJ)(9,3,3)

33.071

Sell

ATR(14)

0.582

Low Volatility

CCI(14)

-55.650

Neutral

Williams %R

57.531

Sell

TRIX(12,20)

1.497

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

7.124

Sell

MA10

7.191

Sell

MA20

6.522

Buy

MA50

5.660

Buy

MA100

5.741

Buy

MA200

5.011

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 42.23%, representing a quarter-over-quarter decrease of 40.78%. The largest institutional shareholder is Invesco, holding a total of 1.77K shares, representing 0.00% of shares outstanding, with 2.63% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Griffiths (Richard Ian)

11.51M

+4.95%

TCG Crossover Management, LLC

3.03M

Invus Public Equities Advisors, LLC

2.91M

+4.36%

Redmile Group, LLC

2.16M

-2.27%

Lombard Odier Asset Management (USA) Corp.

1.85M

Morgan Stanley & Co. LLC

1.13M

-40.44%

Vivo Capital, LLC

1.11M

Nantahala Capital Management, LLC

1.04M

Frazier Life Sciences Management, L.P.

970.13K

-15.54%

Nextech Invest, Ltd.

952.40K

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 2.53, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.38. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.